$2.90
+0.04 (+1.40%)
Open$2.81
Previous Close$2.86
Day High$2.91
Day Low$2.75
52W High$5.55
52W Low$1.03
Volume—
Avg Volume642.7K
Market Cap243.55M
P/E Ratio—
EPS$-1.28
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+1,461.7% upside
Current
$2.90
$2.90
Target
$45.29
$45.29
$33.37
$45.29 avg
$67.77
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 18.99M | 59.72M | 61.79M |
| Net Income | -109,112,779 | -17,457,928 | -16,293,891 |
| Profit Margin | -574.6% | -29.2% | -26.4% |
| EBITDA | -112,808,631 | -19,228,267 | -21,164,861 |
| Free Cash Flow | — | -18,637,383 | -17,592,445 |
| Rev Growth | — | -4.4% | +5.4% |
| Debt/Equity | 0.00 | 0.30 | 0.31 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |